Evidence map›Paper›PMID 42138205›Full record

ReviewInternational journal of molecular medicine2026

Rab27: Molecular switch of tumor exosome secretion (Review).

Mengtian Tang, Zhongjian Zhu, Huaxin Duan, Shiming Tan, Mengzhou Shen, Xianjie Jiang, Qiu Peng, Linda Oyang, Zongyao Ren, Yujuan Zhou and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mengtian Tang *Department of Oncology, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University, Hunan Normal University Health Science Center, Changsha, Hunan 410005, P.R. China.
Zhongjian Zhu *Department of Oncology, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University, Hunan Normal University Health Science Center, Changsha, Hunan 410005, P.R. China.
Huaxin DuanDepartment of Oncology, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University, Hunan Normal University Health Science Center, Changsha, Hunan 410005, P.R. China.
Shiming TanThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism, Changsha, Hunan 410013, P.R. China.
Mengzhou ShenDepartment of Oncology, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University, Hunan Normal University Health Science Center, Changsha, Hunan 410005, P.R. China.
Xianjie JiangThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism, Changsha, Hunan 410013, P.R. China.
Qiu PengThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism, Changsha, Hunan 410013, P.R. China.
Linda OyangThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism, Changsha, Hunan 410013, P.R. China.
Zongyao RenThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism, Changsha, Hunan 410013, P.R. China.
Yujuan ZhouThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism, Changsha, Hunan 410013, P.R. China.
Qianjin LiaoDepartment of Oncology, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University, Hunan Normal University Health Science Center, Changsha, Hunan 410005, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rab proteins are core regulators of vesicle trafficking during membrane transport. As key members of this family, Rab27 comprises two functionally distinct isoforms, Rab27a and Rab27b, and participates in the regulation of exosome secretion by mediating the selective anchoring of multivesicular bodies to the plasma membrane. In tumor cells, Rab27 promotes malignant progression by modulating exosome secretion. Aberrantly expressed Rab27 is associated with the prognosis of patients with cancer, suggesting its potential as a prognostic biomarker for various malignant tumors. Furthermore, the development of novel small‑molecule drugs targeting Rab27 is promising because these drugs can exert antitumor effects through interference with the exosome secretory pathway. The present review systematically summarizes the molecular mechanisms underlying the Rab27‑mediated regulation of exosome secretion and its role in tumorigenesis and cancer progression and discusses the application prospects and challenges of Rab27‑targeted antitumor therapeutic strategies, aiming to provide a reference for basic research and clinical translation of Rab27.

Indexed as

ExosomesNeoplasmsrab27 GTP-Binding ProteinsAnimalsHumansrab GTP-Binding ProteinsRAB27A protein, humanRab27B protein, humanrab27 GTP-Binding Proteinsrab GTP-Binding Proteinsantitumor treatmentbiomarkerexosomesRab27secretiontransport

Identifiers

PMID42138205
PMCPMC13178725

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.